Effectiveness of Alprostadil for Ductal Patency

Area of Science:

• Neonatal Cardiology
• Pediatric Pharmacology
• Congenital Heart Disease Research

Background:

• Infants with ductal-dependent congenital heart disease (DDCHD) require a patent ductus arteriosus (PDA) for systemic circulation.
• Alprostadil is commonly used to maintain ductal patency, but optimal dosing strategies require further investigation.

Purpose of the Study:

• To evaluate the effectiveness of low-dose alprostadil regimens in maintaining PDA in neonates with DDCHD.
• To compare the safety and efficacy of very low-dose versus low-dose alprostadil.
• To describe adverse drug events and prescribing trends associated with alprostadil use.

Main Methods:

• Retrospective observational cohort study of neonates with DDCHD receiving alprostadil.
• Comparison of very low-dose ( < 0.01 mcg/kg/min) versus low-dose (≥ 0.01 mcg/kg/min) alprostadil.
• Effectiveness defined by survival without resuscitation events; adverse events assessed using Naranjo score (≥ 3).

Main Results:

• Alprostadil was effective in 88% of patients, with no significant difference between very low-dose and low-dose groups.
• Adverse drug events were reported in 51% of patients.
• The low-dose group experienced more apnea and pyrexia compared to the very low-dose group.

Conclusions:

• Low-dosage alprostadil is effective for maintaining PDA in neonates with DDCHD.
• Adverse drug events are common but appear less frequent for apnea and pyrexia with very low-dose alprostadil.
• These findings support the use of low-dose alprostadil regimens in managing DDCHD.